COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
12 hedge funds and large institutions have $132K invested in COSCIENS Biopharma Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 18 closing their positions.
0.16% more ownership
Funds ownership: 0.01% → 0.18% (+0.16%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
59% less capital invested
Capital invested by funds: $318K → $132K (-$186K)
59% less funds holding
Funds holding: 29 → 12 (-17)
93% less call options, than puts
Call options by funds: $226K | Put options by funds: $3.05M
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.38K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.34K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$35K |
| 3 |
Millennium Management
New York
|
-$20K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$18K |
| 5 |
VF
Virtu Financial
New York
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| – | -$1K | -52 | Closed |
|
27
Citigroup
New York
| – | -$1K | -39 | Closed |
|
|
SWM
28
Spire Wealth Management
Mclean,
Virginia
| – | -$1K | -33 | Closed |
|
|
TC
29
Truvestments Capital
Sarasota,
Florida
| – | -$1K | -29 | Closed |
|
CSCI Hedge Fund Activity: Q3 2022 in Review
12 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2022, worth a combined $132K — down 59% from $318K a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CSCI and 1 opened new positions — a net loss of 17 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $8.38K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $36.2K sold.
- 12 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2022, down from 29 in Q2 2022.
- Funds reported $132K of COSCIENS Biopharma Inc. Common Stock stock for Q3 2022, down 59% quarter-over-quarter.
- 1 fund opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2022 and 18 closed out, a net change of -17 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2022 was Morgan Stanley, an estimated $8.38K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2022 was Susquehanna International Group, an estimated $36.2K sold.
Based on aggregated 13F filings for Q3 2022.